Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Rheumatoid arthritis drugs market will grow to $30.4 billion by 2025
The global rheumatoid arthritis drugs/therapeutics market size was valued at $20.
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
A new report published by Boston's Institute for Clinical and Economic Review (ICER) concludes that two pricey new CAR-T cell therapies, Novartis AG's Kymriah (tisagenlecleucel)...
A reversal of fortunes: Judge voids order Gilead must pay $2.5B to Merck over a patent dispute
In a reversal of fortunes, a federal judge overturned a jury verdict ordering Gilead Sciences (GILD) to pay $2.
Roche to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
(Reuters) - Swiss drugmaker Roche Holding AG (ROG.
Camber launches generic Celexa oral solution
Camber Pharmaceuticals has added to its portfolio of oral generics.
FDA Approves Apalutamide for Nonmetastatic Prostate Cancer
The US Food and Drug Administration (FDA) today approved apalutamide (Erleada, Janssen) for the treatment of patients with nonmetastatic prostate cancer who are at high risk for diseas...
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany, and Pfizer Inc.
Camber’s generic Viread launches
Camber Pharmaceuticals has launched its generic Viread (tenofovir disoproxil fumarate) tablets.
Merck scraps another late-stage Alzheimer's drug study
NEW YORK (Reuters) - Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer’s drug because it was unlikely to work, adding to the pile-up of failures to find...
Japanese Company Claims Experimental Drug Kills Flu Virus in a Single Day
In the midst of one of the worst flu seasons in several years, a Japanese pharmaceutical company says it has an experimental drug that could make next winter a lot less sickly – not to mention safer...
Tetraphase's antibiotic fails late-stage study, shares plummet
(Reuters) - Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares pl...
Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema
Roche (SIX.
482
483
484
485
486
487
488
489
490
